Healthcare and Life Science
Isogenica and Cube Biotech Unite to Accelerate GPCR Therapeutics
Isogenica, a global leader in synthetic VHH antibody discovery, has announced a strategic collaboration with Cube Biotech, experts in stabilised protein technologies, to tackle one of the most complex challenges in drug discovery: G protein-coupled receptors (GPCRs). ...
From Hit to Clinic: Isogenica and Charles River Collaborate to Accelerate Next-Generation Peptide and VHH Discovery
Every breakthrough begins with discovery. Isogenica, a leader in synthetic VHH antibody and peptide discovery, has announced a collaboration with Charles River, a leading, global provider of drug discovery, development, and manufacturing solutions, to help biotech companies streamline d...
Cerberus Therapeutics Enters into Antibody Discovery Agreement with Isogenica to Advance Immune-Modulating Therapies
Isogenica Ltd., The VHH Company™, today announced an antibody discovery agreement with Cerberus Therapeutics to support the development of targeted immune-modulating therapies using single-domain antibodies. This agreement brings together Cerberus’s KappaLink™ platform — designed to en...
AI in antibody discovery: Why better data still matters
AI and machine learning are becoming increasingly important in antibody discovery, but the field is moving beyond the idea that computational tools will simply replace experimental science. The most valuable progress is happening where AI is integrated with high-throughput screening, st...
Crossing the blood–brain barrier: Why VHHs matter for CNS Biologics
The blood–brain barrier (BBB) remains one of the hardest challenges in biologics development. Designed to protect the central nervous system, it tightly controls which molecules can enter the brain — but this same selectivity prevents many promising therapeutic formats, including antibo...
Beyond liver uptake: How VHHs could support more targeted LNP delivery
Lipid nanoparticles have become one of the most important delivery platforms for next-generation therapeutics, particularly for payloads such as mRNA, siRNA and oligonucleotides. But many programmes still face a major challenge: how to move beyond liver-dominant uptake and achieve more ...
It’s time to govern your team’s AI use
Do you know which AI tools your team is using at work… and what they’re putting into them?Most senior leaders we speak to think they do. Until we dig a little deeper.Generative AI tools like ChatGPT and Gemini have slipped into everyday work incredibly fast. They’re great for produ...
Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell Thermal Cyclers
New PTC Harmony Thermal Cycler Line Expands Access to Reliable, High-Performance PCR Across Academic and Biopharma LaboratoriesHERCULES, Calif.—April 28, 2026—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, an...
Webinar: When Hits Don’t Translate – Challenging Membrane Targets from GPCRs to CD3–TCR
How target presentation and environment shape epitope access, selection outcomes, and functional screening. ...
First letting secured at Sidney Sussex Building, Chesterford Research Park
Cambridge, UK, 28th April 2026: